Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2011. The report details a specific share repurchase transaction executed on October 12, 2011, in accordance with shareholder authority granted at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure and share repurchase activity.
- Shares Purchased: 250,000 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,386 pence per share; lowest price paid was 1,379.5 pence per share.
- Treasury Holdings (Settled): 506,276,370 shares (9.09% of total issued share capital).
- Treasury Holdings (Including Unsettled): 506,876,370 shares (10.01% of current total voting rights).
- Shares in Issue (Excluding Treasury): 5,063,783,917 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 250,000 shares for Treasury. Consequently, the percentage of total voting rights held in Treasury increased to 10.01% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance disclosure confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules and explicitly states it does not constitute an offer to purchase securities.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (506,276,370 settled) against subsequent filings to track ongoing buyback activity.
- Confirm the calculation of total voting rights (5,063,783,917 shares in issue) for disclosure threshold assessments under FSA rules.
- Note that this filing does not contain operational or financial performance data; refer to Form 20-F for comprehensive financial metrics.